Pfizer announced it will discontinue the development of the twice-daily version of its experimental weight loss pill after phase 2 trials showed high rates of side effects in patients. Patients taking the twice-daily pill lost significant weight, but many struggled with side effects like nausea, vomiting, and diarrhea. Over 50% of patients stopped taking the pill due to side effects. This is a setback for Pfizer's hopes to enter the lucrative $90 billion weight loss drug market. Pfizer is behind competitors like Novo Nordisk and Eli Lilly in developing more convenient pill treatments for weight loss.